Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.656
-0.022 (-3.26%)
At close: Nov 20, 2024, 4:00 PM
0.650
-0.006 (-0.93%)
Pre-market: Nov 21, 2024, 7:41 AM EST
Ensysce Biosciences Revenue
Ensysce Biosciences had revenue of $3.42M in the quarter ending September 30, 2024, with 685.26% growth. This brings the company's revenue in the last twelve months to $4.42M, up 40.41% year-over-year. In the year 2023, Ensysce Biosciences had annual revenue of $2.23M, down -11.61%.
Revenue (ttm)
$4.42M
Revenue Growth
+40.41%
P/S Ratio
0.96
Revenue / Employee
$631,629
Employees
7
Market Cap
12.83M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2.23M | -292.86K | -11.61% |
Dec 31, 2022 | 2.52M | -1.01M | -28.54% |
Dec 31, 2021 | 3.53M | -400.01K | -10.18% |
Dec 31, 2020 | 3.93M | 2.17M | 122.86% |
Dec 31, 2019 | 1.76M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Trinity Biotech | 59.13M |
Cosmos Health | 56.04M |
STRATA Skin Sciences | 32.68M |
Vivos Therapeutics | 14.58M |
Sol-Gel Technologies | 11.71M |
Traws Pharma | 226.00K |
AIM ImmunoTech | 190.00K |
ENSC News
- 8 days ago - Ensysce Biosciences Reports Third Quarter 2024 Financial Results - Accesswire
- 14 days ago - Ensysce Biosciences Receives Positive Nasdaq Listing Determination - Accesswire
- 6 weeks ago - Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit - Accesswire
- 7 weeks ago - Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries - Accesswire
- 7 weeks ago - Ensysce Biosciences Receives Notice from Nasdaq - Accesswire
- 2 months ago - Ensysce Biosciences Presenting at Upcoming Meetings - Accesswire
- 2 months ago - Ensysce Biosciences Submits Phase 3 Protocol to the FDA - Accesswire
- 2 months ago - Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024 - Accesswire